雷公藤衍生物celastrol作为YAP抑制剂在系统性硬化症中具有抗纤维化作用
研究探讨雷公藤衍生物celastrol(YAP抑制剂)对系统性硬化症(SSc)皮肤纤维化的作用。方法包括对健康个体和弥漫性皮肤型SSc患者来源的真皮成纤维细胞给予TGFβ1和/或celastrol处理,以及博来霉素诱导的小鼠皮肤SSc模型。结果显示celastrol可减轻TGFβ1诱导的SSc样基因表达模式及SSc患者真皮成纤维细胞的持续纤维化表型,并在小鼠模型中抑制博来霉素诱导的网状成纤维细胞和Hippo/YAP相关基因表达及YAP核定位。作者认为拮抗YAP通路的化合物如celastrol可能是SSc皮肤纤维化的潜在治疗。
要点
- celastrol可损害TGFβ1诱导真皮成纤维细胞产生SSc样基因表达模式的能力。
- celastrol减轻从SSc患者皮损培养的真皮成纤维细胞的持续纤维化表型。
- 博来霉素诱导的小鼠皮肤SSc模型中celastrol抑制YAP核定位及相关基因表达。
核心结论
- 数据阐明了皮肤中在纤维化时被激活的生态位,并提示拮抗YAP通路的化合物如celastrol可能是SSc皮肤纤维化的潜在治疗。
研究设计与样本
- 研究使用健康个体和弥漫性皮肤型SSc患者的真皮成纤维细胞,在有无TGFβ1及有无celastrol条件下处理。
- 使用博来霉素诱导的小鼠皮肤SSc模型,在有无celastrol条件下观察。
- 纤维化通过RNA测序、实时PCR、空间转录组分析、Western blot、ELISA和组织学分析评估。
主要发现
- 在真皮成纤维细胞中,celastrol损害TGFβ1诱导SSc样基因表达模式的能力,包括细胞通讯网络因子2、I型胶原和TGFβ1。
- celastrol减轻从SSc患者皮损培养的真皮成纤维细胞的持续纤维化表型。
- 在博来霉素诱导的小鼠皮肤SSc模型中,观察到网状成纤维细胞和Hippo/YAP簇相关基因表达增加;celastrol抑制这些博来霉素诱导的变化并阻断YAP的核定位。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic sclerosis (SSc) is characterised by extensive tissue fibrosis maintained by mechanotranductive/proadhesive signalling. Drugs targeting this pathway are therefore of likely therapeutic benefit. The mechanosensitive transcriptional co-activator, yes activated protein-1 (YAP1), is activated in SSc fibroblasts. The terpenoid celastrol is a YAP1 inhibitor; however, if celastrol can alleviate SSc fibrosis is unknown. Moreover, the cell niches required for skin fibrosis are unknown. METHODS: Human dermal fibroblasts from healthy individuals and patients with diffuse cutaneous SSc were treated with or without transforming growth factor β1 (TGFβ1), with or without celastrol. Mice were subjected to the bleomycin-induced model of skin SSc, in the presence or absence of celastrol. Fibrosis was assessed using RNA Sequencing, real-time PCR, spatial transcriptomic analyses, Western blot, ELISA and histological analyses. RESULTS: In dermal fibroblasts, celastrol impaired the ability of TGFβ1 to induce an SSc-like pattern of gene expression, including that of cellular communication network factor 2, collagen I and TGFβ1. Celastrol alleviated the persistent fibrotic phenotype of dermal fibroblasts cultured from lesions of SSc patients. In the bleomycin-induced model of skin SSc, increased expression of genes associated with reticular fibroblast and hippo/YAP clusters was observed; conversely, celastrol inhibited these bleomycin-induced changes and blocked nuclear localisation of YAP. CONCLUSIONS: Our data clarify niches within the skin activated in fibrosis and suggest that compounds, such as celastrol, that antagonise the YAP pathway may be potential treatments for SSc skin fibrosis.
引用
- Chitturi P, Xu S, Ahmed Abdi B, et al. Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis. Ann Rheum Dis. 2023. PMID: 37328193. doi:10.1136/ard-2023-223859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。